ProtiFi
Private Company
Total funding raised: $6.2M
Overview
ProtiFi is a private, commercial-stage company that has established itself as a leader in omics sample preparation technology since its founding in 2018. Its core business revolves around physical consumables (kits, plates, columns) and a complementary SaaS data analysis platform, catering primarily to academic, pharmaceutical, and research laboratories. The company's value proposition is built on demonstrable improvements in reproducibility, recovery rates, and workflow speed, as evidenced by widespread adoption and citations in thousands of scientific papers. ProtiFi operates in the rapidly growing proteomics and multi-omics tools market, with a clear focus on enabling precision biology through robust sample prep and data interpretation.
Technology Platform
Proteomics and multi-omics sample preparation technology (S-Trap, Si-Trap, Tryp-N) combined with a cloud-based data analysis and visualization platform (SimpliFi).
Funding History
2Opportunities
Risk Factors
Competitive Landscape
ProtiFi competes in the sample prep segment against large vendors like Thermo Fisher Scientific (Pierce kits), Bio-Rad, and MilliporeSigma, as well as specialized proteomics companies. For data analysis, it competes with a wide range of bioinformatics software from open-source projects (e.g., MaxQuant, Skyline) to commercial platforms (e.g., Biognosys' Spectronaut, Thermo's Proteome Discoverer). Its differentiation lies in the specific performance of S-Trap for challenging samples and the integrated, accessible nature of its SimpliFi platform.